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Abstract
 
Aims
 
To develop a model for estimating the immediate and long-term health-
care costs associated with seven diabetes-related complications in patients with
Type 2 diabetes participating in the UK Prospective Diabetes Study (UKPDS).
 
Methods
 
The costs associated with some major complications were estimated
using data on 5102 UKPDS patients (mean age 52.4 years at diagnosis). In-patient
and out-patient costs were estimated using multiple regression analysis based on
costs calculated from the length of admission multiplied by the average specialty
cost and a survey of 3488 UKPDS patients’ healthcare usage conducted in
1996–1997.
 
Results
 
Using the model, the estimate of the cost of first complications were
as follows: amputation £8459 (95% confidence interval £5295, £13 200); non-
fatal myocardial infarction £4070 (£3580, £4722); fatal myocardial infarction
£1152 (£941, £1396); fatal stroke £3383 (£1935, £5431); non-fatal stroke
£2367 (£1599, £3274); ischaemic heart disease £1959 (£1467, £2541); heart
failure £2221 (£1690, £2896); cataract extraction £1553 (£1320, £1855); and
blindness in one eye £872 (£526, £1299). The annual average in-patient cost of
events in subsequent years ranged from £631 (£403, £896) for heart failure to
£105 (£80, £142) for cataract extraction. Non-in-patient costs for macrovascu-
lar complications were £315 (£247, £394) and for microvascular complications
were £273 (£215, £343) in the year of the event. In each subsequent year the
costs were, respectively, £258 (£228, £297) and £204 (£181, £255).
 
Conclusions
 
These results provide estimates of the immediate and long-term
healthcare costs associated with seven diabetes-related complications.
Diabet. Med. 20, 442–450 (2003)
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Introduction
 
The range of therapies to prevent, delay or treat Type 2
diabetes-related complications is rapidly expanding, and it is
increasingly expected that their costs and benefits should be
properly evaluated before they are widely adopted. Recent
economic evaluations of policies for the management of Type
2 diabetes mellitus have shown that the increased costs of
implementing more intensive blood glucose and blood pres-
sure control policies are partly offset by substantial savings
associated with treating fewer diabetes-related complications
[1,2]. As future savings from reducing or preventing diabetes
complications may have a large effect on the overall costs of
other diabetes therapies, it is important to have accurate estim-
ates of the medical costs of diabetes-related complications.
Many costing studies have documented the total burden of
diabetes to the health system and society, with varying focus
on the impact of diabetes-related complications [3]. While
these aggregate cost of illness studies quantify the scale of the
problem, they convey no information on the cost-effectiveness
of existing or alternative interventions. Such analyses require
patient-level data collected prospectively in a well-designed
clinical trial, or the use of models that simulate the impact of
alternative interventions on the probability and cost of experi-
encing diabetes-related complications [4,5]. A small number of
studies have reported cost estimates for a limited range of com-
plications [6–9], but a recent review of the literature concluded
there are ‘… no recent papers that provide comprehensive
patient-level cost estimates for the majority of relevant diabetic
complications’ [7].
This scarcity of cost data is a serious handicap for researchers
intending to evaluate alternative interventions for the man-
agement of Type 2 diabetes. The purpose of this study is to
address this deficiency using prospectively collected data from
the United Kingdom Prospective Diabetes Study (UKPDS),
a large trial of therapies for diabetes. A regression-based
approach is employed to estimate the short-term and long-
term annual hospital and non-hospital costs associated with
seven major diabetes-related complications: myocardial in-
farction (MI); stroke, angina or ischaemic heart disease (IHD);
heart failure; blindness in one eye; amputation and cataract
extraction.
 
Subjects and methods
 
Research setting and study population
 
The UKPDS was conducted from 1977 to 1997 in 23 participat-
ing centres in England, Scotland and Northern Ireland. A total
of 5102 patients with newly diagnosed Type 2 diabetes were
recruited to the study, with a mean age at entry of 52.4 years (
 
SD
 
8.8 years). Of the study population, 58% were men, and in
regard to ethnic composition 81% were Caucasian, 10% were
Indian/Asian, 8% were Afro-Caribbean, and 1% were from
other ethnic groups. From this total, eligible patients were then
randomized into blood glucose control and blood pressure con-
trol studies. The median duration of follow-up in the study was
10.3 years, and this generated 55 942 patient years of data. De-
tails of the study design and the main clinical results have been
published elsewhere [10].
 
Identification of clinical events
 
All patients attended UKPDS clinics every 3 or 4 months for the
duration of the study. At each visit they were assessed to deter-
mine the occurrence of any clinical events or hospital episodes
since the previous visit. Full clinical information on the event
was obtained, and this was presented to the UKPDS Endpoint
Adjudication Committee where two clinical assessors independ-
ently classified the event into predefined categories based on the
9th revision of the International Classification of Diseases
(ICD9) codes. If any disagreements could not be resolved by
arbitration, the information was submitted to a further panel of
assessors for a final decision.
 
Resource use data
 
Information on hospital in-patient stays was collated by each
clinic based on patient interviews at every clinic visit, death
records and hospital records. Where an in-patient stay had
occurred, details were obtained from the relevant hospital of
dates of admission and discharge, reasons for admission, and
any major procedures undertaken. All hospital episodes were
subsequently allocated to one of 40 national specialty codes
[11] using information from the hospital or assessment by a
panel of two clinicians based on reason for admission, ICD
code and/or the procedures undertaken. In approximately 16%
of cases (predominantly in the earliest years of the study) the
length of stay was not recorded and so multiple imputation
methods were applied to replace the missing data [12]. The vari-
ance was increased according to standard rules [13] to reflect
the uncertainty surrounding the missing data. The cost of each
episode of hospitalization was estimated by multiplying the
length of stay by the average cost of the respective specialty,
based on an average (after adjusting for inflation) of the
Department of Health’s NHS Trust Financial Returns (TFR2)
for 1997/8 and 1998/9 [14]. The average cost per day of the 10
specialties most frequently allocated to the hospital episodes
of UKPDS patients, and the mean length of stay of recorded
episodes in each specialty, are reported in Table 1. These spe-
cialties accounted for just over 80% of all episodes of UKPDS
patients over the duration of the study. The average cost per
patient day ranged from £165 in the specialty Other Medicine
to £534 in Ophthalmology and the average length of stay
ranged from 13.6 days in Neurosurgery to 3.6 days in Oph-
thalmology. After multiplying the cost per patient day by the
length of stay for each episode the costs were then aggregated
into annual costs for each patient relative to their entry into
the study (which coincides with diagnosis of diabetes).
Information on non-in-patient health care resources was
obtained using a different method. A cross-sectional survey of
3488 UKPDS patients was conducted between January 1996
and September 1997, using a questionnaire distributed at clinic
visits or by post to patients who did not attend clinics during the
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survey period. This survey recorded information on all home,
clinic, and telephone contacts with general practitioners, nurses,
podiatrists, opticians, and dieticians, and with eye and other
hospital out-patient clinics over the 4 months prior to the
survey. The total costs over this period were estimated by
multiplying the number of contacts by unit costs for each type
of contact, derived from UKPDS clinics and from published
sources [15], and the resulting total cost was then annualized.
 
Methods of analysis
 
We examine the relationship between healthcare costs and seven
clinical event categories defined in Table 2 [16]. The number of
first events in each category experienced by patients during the
study is also reported. These ranged from 828 first non-fatal
MIs to 67 first amputations.
Hospital in-patient costs are estimated for each of these
seven complications. Previous studies of diabetes-related com-
plications have shown that their costs have a distinct profile
over time [17]. To address this, we estimate both the immedi-
ate or acute impact of the first diabetes-related complication
(i.e. the effect in the year the complication occurs) and the
long-term impact (i.e. the effect in all subsequent years) on in-
patient costs.
The occurrence of complications also has an impact on non-
in-patient costs, as many patients will require subsequent care
and rehabilitation. However, because data on these costs were
obtained from a single cross-sectional study, there is insufficient
information to distinguish between each type of diabetes-related
complication. Consequently, in the analysis of non-in-patient
costs we combine complications into two major groupings:
macrovascular complications (MI, stroke, IHD, heart failure)
and microvascular and eye-related complications (blindness
in one eye, amputation and cataract extraction).
 
Statistical analysis
 
Healthcare cost data often have several characteristics that
must be addressed through the careful selection of appropriate
statistical analyses. Typically, within a defined period (e.g.
1 year) a significant proportion of individuals have no contact
with some types of healthcare providers and so incur no costs.
However, amongst the individuals who do make use of health
services, the distribution of costs is frequently highly skewed
due to the presence of relatively few individuals incurring very
high healthcare costs [18–20].
To estimate the cost of various complications we employ
a two-part model in our analysis. In the first part, logistic
regression is used to model the probability of incurring some
hospital costs within a single patient-year time period. The
dependent variable is set equal to 1 in any patient year an indi-
vidual incurs costs. To determine the impact of various clinical
events on the probability of attending hospital we include an
indicator variable for each event and variables to adjust for
age (centred by deducting 55 from current age) and sex. In the
second part the total hospital costs incurred, conditional on
Specialty
Proportion of 
all episodes, %
Cost per 
patient day*
Mean length of stay (days) 
of recorded episodes
Cardiology 20 £408 7.7
Other medicine 11 £165 6.4
General surgery 9 £266 8.6
Urology 8 £256 5.6
Orthopaedics 8 £266 11.6
Gastroenterology 6 £224 6.7
Ophthalmology 6 £534 3.6
Gynaecology 4 £318 6.8
Neurosurgery 4 £421 13.6
Oncology 4 £340 9.4
Total 80
*Source: Annual financial returns of NHS trusts (TFR2 return), 1997/98 and 1998/99 [14].
Table 1 Cost per day of the 10 specialties that 
were most frequently allocated to the hospital 
episodes of UKPDS patients
Table 2 Diabetes-related complications included in the regression analysis, with diagnostic definitions and number of first events in each category
Category Predefined diagnostic definitions Number of first events
Myocardial infarction ICD9 Code 410 828
Stroke Major stroke with symptoms that persist more
than 1 month (ICD9 Codes 430 to 434.9 and 436)
271
Ischaemic heart disease ICD9 Code 411 to 414.9 319
Heart failure ICD9 Codes 428 to 428.1 166
Blindness in one eye ICD9 Code 369 to 369.9 163
Amputation Major limb complications requiring amputation
of digit or limb for any reason
67
(ICD9 Codes 5.845 to 5.848)
Cataract extraction ICD9 Codes 5.143 to 5.146 297
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incurring any costs, is estimated. As the events amputation
and cataract extraction are treatments requiring hospitaliza-
tion, we exclude them from the first-stage equation (i.e. the
probability of attending hospital is set equal to 1).
When modelling the second part of the model it is important
to recognize that the positive component of hospital costs is
skewed and hence some episodes with extremely high costs can
overly influence the model’s parameters. To model these
data we employ a generalized linear model (GLM) [21], which
assumes patient characteristics and complications have a
multiplicative effect on costs (see Statistical Appendix for
further discussion). Estimates of the probability of incurring
costs, the costs conditional on a cost being incurred and the
expected cost (the product of probability and conditional cost)
can be calculated using the model. Similar methods were used to
estimate the likelihood that non-hospital costs were incurred
within a single time period of 4 months (the period covered by
the survey) and the total non-hospital costs incurred conditional
on incurring any costs. These costs were then annualized.
 
Results
 
Hospital in-patient costs
 
Table 3 reports the coefficients and standard errors for the
two-part model that can be used to predict hospital in-patient
costs. The first part is a logistic regression equation to model
the annual probability of incurring some hospital in-patient
cost. In the second, a GLM is used to model cost of hospitali-
zation conditional on at least one event occurring and the
multiplicative effect of each coefficient is also reported to assist
in interpretation.
All equations include variables representing the patients’ age
and sex, and sets of indicator variables for the occurrence of
diabetes-related complications in the year in question, or in
any previous year. These equations can be used to estimate the
annual hospital costs based on the patient’s characteristics
and history of complications (the Statistical Appendix below
contains a worked example).
Table 4 reports predictions from the logistic regression
equations for an individual with characteristics set to reflect
the average values for the UKPDS study population (i.e. a male
aged 58.6 years) for the first complication of any type. The
second column of the table shows the annual probability of
this individual incurring any hospital in-patient costs. Patients
who had no complications had a probability of incurring
any hospital in-patient costs in any single year of 0.06; that is,
approximately 6% of patients who did not have any diabetes-
related complications in a given year nevertheless were admit-
ted to hospital as an in-patient and consequently incurred
some hospital costs. Table 4 also reports the annual probabil-
ity of incurring any hospital costs for each type of event for
Table 3 Regression equations to derive annual probability of incurring hospital costs, and costs of hospital care conditional on incurring a cost (5102 
patients and 55 942 patient years)
Part 1: Equation to derive annual 
probability of incurring hospital costs 
Part 2: Equation to derive annual cost of hospital care, 
conditional on costs being incurred 
Variable Coefficient Standard error Coefficient Standard error Multiplicative effect
Constant −2.674** 0.036 7.902** 0.043
Current age –55 (years) 0.017** 0.002 0.013** 0.002 1.01
Male (= 1) −0.108** 0.041 −0.106* 0.052 0.90
Event during year indicator
Fatal MI 3.743** 0.137 −0.485** 0.107 0.62
Non-fatal MI 4.091** 0.148 0.696** 0.067 2.01
Fatal stroke 4.108** 0.356 0.508 0.279 1.66
Non-fatal stroke 2.087** 0.172 0.987** 0.136 2.68
Ischaemic heart disease 2.363** 0.133 0.627** 0.128 1.87
Heart failure 2.822** 0.191 0.508** 0.115 1.66
Blindness in one eye 1.330** 0.198 0.541** 0.204 1.72
Amputation — — 1.202** 0.253 3.33
Cataract extraction — — −0.493** 0.134 0.61
History of event†
Non-fatal MI 0.809** 0.083 0.348** 0.076 1.42
Non-fatal stroke 0.328* 0.134 0.155 0.141 1.17
Ischaemic heart disease 0.812** 0.083 0.405** 0.077 1.50
Heart failure 1.016** 0.135 0.477** 0.146 1.61
Blindness in one eye 0.471** 0.135 0.147 0.136 1.16
Amputation 0.309 0.216 0.358 0.207 1.42
Cataract extraction −0.093 0.105 −0.316** 0.142 1.17
*P < 0.05; **P < 0.01.
†Refers to events that occurred in previous patient years.
Part 1 is derived using a logistic regression model, part 2 is derived using a generalized linear model. MI, Myocardial infarction.
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someone who has not previously had any of these complica-
tions. The immediate impact of complications such as a MI is
to increase greatly the probability of incurring some hospital
in-patient costs (e.g. a 74% probability of incurring hospital
costs for a fatal MI and 80% for a non-fatal MI). These data
suggest that approximately one-fifth of all non-fatal MIs do
not incur any hospital in-patient costs in the year in which they
occur, and this may be due to patients not being diagnosed as
having had an MI until a subsequent investigation. Similarly,
a proportion of non-fatal strokes and instances of heart failure
are not associated with in-patient costs in the year in which
they occur, while IHD and blindness in one eye are primarily
treated in a non-in-patient setting.
Table 4 also shows the probability of incurring hospital
in-patient costs in subsequent years. This indicates that the
rate of hospitalization continues to be significantly higher than
the 6% rate experienced by individuals who have not had any
complications. For example, patients who have experienced a
heart failure are predicted to have a 15% probability of incur-
ring hospital in-patient costs for all subsequent years.
Column 3 of Table 4 shows the estimated mean hospital
in-patient costs associated with each complication, conditional
on some hospital in-patient costs being incurred calculated
using the GLM equation reported in Table 3. Thus, if the
patient incurred hospital in-patient costs in the year in which
they had a non-fatal MI, these costs averaged £5104 (£4486,
£5806), while patients who experienced an amputation on
average incurred hospital in-patient costs of £8459 (£5220,
£13 706) in that year. For all complications except fatal MI
and cataract extraction, these hospital in-patient costs are
substantially higher than the £2543 (£2406, £2697) incurred
on average by the 6% of patients with no complication who
nevertheless were admitted to hospital as in-patients.
Finally, column 4 of Table 4 shows the product of columns
2 and 3: i.e. the expected hospital in-patient costs associated
with each complication. For example, someone who experi-
ences a non-fatal stroke has a 35% probability of incurring
hospital in-patient costs in the year the event occurred, the cost
for these 35% of patients was £6822 (£5255, £8858) and so
the expected or unconditional hospital in-patient costs associ-
ated with a non-fatal stroke are the product of these, or £2367
(£1599, £3274). Note that the 95% confidence intervals
around these estimates are not symmetrical, due to the effects
of retransformation.
 
Non-in-patient costs
 
Table 5 reports the coefficients and standard errors for the
comparable regression equations relating to non-in-patient
costs. These can also be used to calculate the annual non-in-
patient costs for an individual based on their age and sex and
history of macrovascular and microvascular and eye-related
Table 4 Estimated probability of incurring some hospital in-patient costs, estimated annual hospital in-patient costs conditional on cost being incurred, 
and expected mean cost, for a representative individual by first diabetes-related complication, during year of complication and in subsequent years*
Complication
Mean (95% CI) probability 
of incurring some hospital 
in-patient costs
Estimated annual hospital 
in-patient costs (95% CI) 
conditional on cost being incurred
Expected mean (95% CI) 
hospital in-patient 
cost of complication†
Column 1 Column 2 Column 3 Column 4
No complications 0.06 (0.06, 0.07) £2543 (2406, 2697) £157 (145, 170)
Estimates for the year in which the event occurred
Fatal MI 0.74 (0.68, 0.78) £1567 (1279, 1919) £1152 (941, 1396)
Non-fatal MI 0.80 (0.75, 0.84) £5104 (4486, 5806) £4070 (3580, 4722)
Fatal stroke 0.80 (0.67, 0.89) £4227 (2454, 7280) £3383 (1935, 5431)
Non-fatal stroke 0.35 (0.27, 0.43) £6822 (5255, 8858) £2367 (1599, 3274)
Ischaemic heart disease 0.41 (0.35, 0.48) £4760 (3736, 6064) £1959 (1476, 2541)
Heart failure 0.53 (0.43, 0.62) £4227 (3431, 5208) £2221 (1690, 2896)
Blindness in one eye 0.20 (0.14, 0.27) £4370 (3219, 5933) £872 (526, 1299)
Amputation 1 £8459 (5220, 13706) £8459 (5295, 13200)
Cataract extraction 1 £1553 (1278, 1888) £1553 (1320, 1855)
Estimates for each year subsequent to the year in which the event occurred
Non-fatal MI 0.13 (0.11, 0.15) £3603 (3134, 4142) £464 (377, 578)
Non-fatal stroke 0.08 (0.07, 0.11) £2970 (2278, 3872) £249 (166, 357)
Ischaemic heart disease 0.13 (0.11, 0.15) £3814 (3291, 4420) £493 (392, 606)
Heart failure 0.15 (0.12, 0.19) £4097 (3148, 5331) £631 (403, 896)
Blindness in one eye 0.10 (0.07, 0.12) £2945 (2349, 3692) £281 (189, 401)
Amputation 0.08 (0.06, 0.12) £3639 (2445, 5416) £300 (154, 531)
Cataract extraction 0.06 (0.05, 0.07) £1854 (1464, 2349) £105 (80, 142)
*The characteristics of the representative individual were set to the UKPDS mean population values, i.e. a male who is 58.63 years of age.
†Product of probability and conditional cost. MI, Myocardial infarction.
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complications. Table 6 reports for the cost of a first complica-
tion for an individual with characteristics set to the average
values for the UKPDS study population (i.e. a male aged
58.6 years). For patients with no complications the probability
of incurring some non-in-patient costs in any year is 76%. For
patients with macrovascular complications this probability
increases to 91% in the year the event occurs and 86% in sub-
sequent years and patients with microvascular complications
97% and 83%, respectively.
 
Discussion
 
In this study we have reported the results of a regression
analysis on a large patient-specific dataset to obtain empirical
estimates of the hospital in-patient costs and non-in-patient
healthcare costs associated with a set of diabetes-related
complications. It is important to stress that these are not
simply the healthcare costs that are administratively allocated
to events (e.g. the average cost of an in-patient admission for
a non-fatal stroke). Instead they represent an estimate of the
increase in all healthcare costs in the year in which the com-
plication occurs. Thus, the hospital in-patient costs reported
here for a non-fatal stroke will capture any in-patient stays
directly associated with the stroke, but also the potential indi-
rect impact of the stroke, e.g. on lengths of in-patient stay for
other conditions.
Our results indicate the substantial impact of many diabetes-
related complications on hospital costs, not only in the year in
which the event occurs, but in permanently raising the average
level of hospital costs in all subsequent years. This could be due
either to subsequent occurrences of the same complication, or
because patients with a history of diabetes-related complications
Table 5 Regression equations to derive annual probability of incurring non-in-patient costs, and costs of non-in-patient care conditional on incurring 
a cost (3460 patients)
Part 1: Equation to derive annual 
probability of incurring non-in-patient costs
Part 2: Equation to derive non-in-patient costs, 
conditional on costs being incurred 
Variable Coefficient Standard error Coefficient Standard error Multiplicative effect
Constant 1.658 0.086 4.475 0.044
Current age –55 (years) 0.023** 0.005 0.003 0.003 1.00
Male (= 1) −0.604** 0.098 −0.229 0.049** 0.80
Event during year indicator
Macrovascular event 1.142** 0.468 0.501 0.156** 1.65
Microvascular event 2.181* 1.014 0.291 0.193 1.33
History of event
Macrovascular event 0.720** 0.170 0.358 0.072** 1.43
Microvascular event 0.456* 0.229 0.204 0.096* 1.22
*P < 0.05; **P < 0.01. Part 1 equation derived from logistic regression, Part 2 equations derived from generalized linear model.
Table 6 Estimated probability of incurring some non-in-patient costs, estimated non-in-patient costs conditional on cost being incurred, and expected 
mean cost*
Complication
Mean (95% CI) probability 
of incurring some 
non-in-patient cost†
Estimated non-in-patient costs 
(95% CI) conditional on cost 
being incurred†
Expected mean
(95% CI) annualized 
non-in-patient cost
Column 1 Column 2 Column 3 Column 4
No complication 0.76 (0.74, 0.78) £70 (66, 76) £159 (149, 173)
Estimates for the year in which the event occurred
Macrovascular 0.91 (0.83, 0.98) £116 (94, 142) £315 (247, 394)
Microvascular 0.97 (0.88, 1.00) £94 (75, 118) £273 (215, 343)
Estimates for each year subsequent to the year in which the event occurred
Macrovascular 0.86 (0.83, 0.90) £101 (88, 114) £258 (228, 297)
Microvascular 0.83 (0.77, 0.89) £82 (74, 99) £204 (181, 255)
*All costs are for a representative individual (set to the UKPDS mean population values, i.e. a 58.63-year-old male) by first diabetes-related 
complication, during year of complication and in subsequent years.
†Costs for a 4-month period only. All costs in 1999 UK pounds sterling.
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have a greater propensity to require more hospitalizations of
longer duration due to increased frailty compared with those
free of complications.
The estimates we have reported are based on first events for
a patient with average characteristics. These models can also
be used to calculate estimates of costs for patients with other
characteristics and for various combinations of complications.
To facilitate use of these models we have written a program
that can be used to calculate hospital and non-hospital costs
which can be downloaded from the Health Economics
Research Centre website (www.ihs.ox.ac.uk/herc).
It is interesting to compare our estimates with results
from other sources such as specific costing studies or English
Department of Health reference costs. For example, our
estimates indicate that the annual hospital costs for a fatal
MI are £1567 (£1279, £1919) and for a non-fatal MI are
£5104 (£4486, £5806). These are significantly higher than the
Department of Health reference cost for a finished consultant
episode for a MI with complications of £1479 in the general
population [22], and support previous research suggesting that
cost analyses based on utilization labelled to particular com-
plications significantly underestimate the true incremental
costs of complications of diabetes [17].
We have not reported results for patients with end-stage
renal disease, due to the small numbers of patients (25 in the
main UKPDS randomization) with this complication at the
end of the trial follow-up period. Fortunately, this is an area in
which many bottom-up costing studies have been performed:
data from one such large UK study suggest that the annual cost
per patient (with and without diabetes) for all hospital costs
associated with renal dialysis averaged £20 902 in 1996 prices,
and also suggest that the presence of diabetes does not lead to
a significant difference in treatment-specific costs compared
with non-diabetic patients [23], although it may lead to a
lower probability of renal transplantation [24].
The results relating to in-patient costs are based on clinical
practice in the UK from 1977 to 1997—the period covered by
the study. While there are significant advantages in using long-
term follow-up data in order to quantify fully the cost of com-
plications, several important factors should be considered if
these results are used to estimate the cost of complications in
other populations or time periods. First, UKPDS patients were
newly diagnosed and tended to be relatively younger than peo-
ple with Type 2 diabetes in the general population, and so the
costs reported here may not reflect the resource use associated
with complications of some older patients in the general
population. Second, the treatment protocols for some com-
plications are changing over time, for example, coronary stents
are increasingly used in the treatment of patients with IHD and
this will impact on the future costs associated with this com-
plication. Finally, the probability of hospitalization and cost of
each complication conditional on being hospitalized reported
here are likely to differ in other countries, particularly the USA.
In the absence of other data, one option for the analyst want-
ing to employ these costs on other populations and healthcare
settings would be to regard the results reported here as a form
of relative risk in relation to individuals not experiencing
complications. Thus, a macrovascular complication could be con-
sidered to double non-hospital costs in the year it occurs relative
to someone not experiencing a complication, and in subsequent
years leaves them elevated by approximately 60% compared
with the no complication group (Table 6), but further invest-
igation of the validity of this approach would be very useful.
Although the randomized phase of the UKPDS finished
in 1997, follow-up continued beyond that date and substan-
tial additional information on complications and hospital in-
patient costs of UKPDS patients will become available in the
future. This will permit re-estimation and validation of the
results reported here, as well as facilitate an examination of
how recent changes in treatment protocols impact on costs.
Meanwhile, the results reported here provide evidence of the
healthcare cost impact of specific diabetes-related complica-
tions that has hitherto been unavailable. They should be of
interest to other economists and health service researchers,
particularly those wishing to assess within a modelling frame-
work the cost-effectiveness of interventions for Type 2 dia-
betes that prevent complications.
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Statistical appendix
 
Separate statistical analyses were employed in modelling the
inpatient and non-in-patient costs. In the case of in-patient
cost, the data was characterized by repeated observations on
each patient for the years they participated in the UKPDS.
Given the structure of the data we used a random effects
panel data model for both stages of the two-part model. In
particular:
where 
 
C
 
it
 
 are the total hospital costs for the 
 
i
 
th patient (
 
i
 
 = 1 ...
 
 n
 
)
in year 
 
t
 
 of the study (
 
t
 
 = 1, … ,
 
 T
 
) and  are variables (
 
j
 
 = 1 ...
 
 J
 
)
that influence costs including age, sex, indicator variables rep-
resenting the occurrence of diabetes-related complications. To
estimate the immediate impact of complications we include an
indicator variable that is set to 1 in the year that the event
occurs. A second indicator variable is included to estimate the
long-term effect that is set equal to 1 for all subsequent years
while the patient is participating in the study. In the random
effects model the error term is divided into two parts, 
 
µ
 
i
 
 an
unobservable individual specific effect independently identi-
cally distributed with zero mean and variance of  (i.e.
 
µ
 
i
 
 IID(0, )) and 
 
v
 
it
 
 which denotes the remaining error term
(
 
µi IID(0, )). In the first part a logistic regression is applied
to the panel data and the predicted probability of incurring
hospital costs for each event is calculated:
(1)
where αj is the estimated coefficient for the jth variable. In the
second stage of the two-part model we use a GLM with a log
link function on the assumption that:
(2)
where βj is the coefficient on the jth variable in the GLM equa-
tion. Diagnostic tests [20] indicate that the gamma family
should be used to specify the mean–variance relationship.
Expected or mean costs were calculated for each complication
conditional on having positive hospital costs. The overall estim-
ate of hospital costs is then .
It is important to note that a GLM with a log link function
assumes that complications have a multiplicative effect on
overall costs and so patients with several complications will
incur much higher costs than if the costs of complications were
assumed to be additive (as in traditional linear regression).
Only a limited number of patients in the UKPDS experienced
more than two complications and so the validity of predicting
costs using a GLM in this context needs to be determined when
the follow-up data are available. We have therefore also estim-
ated a model using ordinary least squares (OLS) regression
that could be used to provide alternative estimates (particu-
larly for patients with multiple complications) and these along
with GLM estimates can be downloaded from our website
(www.ihs.ox.ac.uk/herc).
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The coefficients for βj and αj reported in Tables 3 and 5 can
be used to calculate the cost of different complications, for
example, to calculate the annual hospital costs of a male who
is 58.63 years of age without a previous history of complica-
tions who has a non-fatal MI. First the annual probability of a
hospitalization must be calculated. Using the values for
the relevant coefficients αConstant, αage, αmale and αnon-fatal MI
of −2.674, 0.017, −0.108 and 4.091 in Equation 1 the pro-
bability of this individual incurring hospital costs in year 1 is:
The total hospital costs conditional on the patient attending
hospital during the year can then be calculated using the GLM
equation, which is also reported in Table 3. The relevant
values for the coefficients βConstant, βage, βmale and βnon-fatal MI
are 7.902, 0.013, −0.106 and 0.696 and so using Equation 2
the hospital cost are: 
E(Ci l | Ci l > 0, Xi l) = exp(7.902 + 0.013 × (58.63 − 55) − 0.106 × 1 + 0.696 × 1)
= 5111
which is slightly greater than £5104 reported in Table 4 which
was calculated using coefficients accurate to a greater number
of decimal places. The estimate of expected hospital costs is
the product of estimates from parts 1 and 2.
The 95% CI for estimates of the cost for complications
reported in Tables 4 and 6 are obtained through non-parametric
bootstrapping involving 1000 replications. This was done by
randomly re-sampling individuals with replacement and
re-estimating the equations. Costs were then calculated and
rank-ordered, and the 25th and 975th estimates were taken as
the confidence limits.
The analysis of non-in-patient costs is based on a similar
approach, but was based on data from a cross-sectional survey
conducted towards the end of the trial. For methodological
consistency we assign non-in-patient costs to the patient
year in which the survey is conducted (denoted as year s) and
employ the same two-part approach but with t = s. The
coefficients of the equations reported in Table 5 can be used to
calculate non-in-patient costs based on the patients’ character-
istics and history of complications.
Pr(   | )  
exp( .   .   ( .   )  .     .   )
(   exp( .   .   ( .   )  .     .   )) 
 .
C Xi i
j
l l> =
− + × − − × + ×
+ − + × − − × + ×
=
0
2 674 0 017 58 63 55 0 108 1 4 091 1
1 2 674 0 017 58 63 55 0 108 1 4 091 1
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